Abstract:Julien Ghelfi, 1– 3, &ast Zuzana Macek Jilkova, 1, 3, 4, &ast Christian Sengel, 2 Bleuenn Brusset, 4 Yann Teyssier, 2 Charlotte Costentin, 1, 3, 4 Marion Mercey-Ressejac, 3, 4 Lucile Dumolard, 1, 3 Marc Manceau, 5 Eliott Mathieu, 2 Ivan Bricault, 1, 2 Thomas Decaens 1, 3, 4 1 University of Grenoble-Alpes, Saint Martin d'Hères, France; 2 Department of Radiology, Grenoble-Alpes University Hospital, Grenoble, France; 3 Institute for Advanced Biosciences - INSERM U1209/CNRS UMR 5309/University of Grenoble-Alpes, La Tronche, France; 4 Department of Hepatology and Gastrointestinal Medical Oncology, Grenoble-Alpes University Hospital, Grenoble, France; 5 Clinical Pharmacology Unit, Inserm Clinical Research Center, Grenoble-Alpes University Hospital, Grenoble, France &astThese authors contributed equally to this work Correspondence: Julien Ghelfi, Department of Radiology, Grenoble-Alpes University Hospital, Boulevard de la Chantourne, Grenoble, 38000, France, Tel +33 476768909, Email Zuzana Macek Jilkova, Department of Hepato-Gastroenterology, Grenoble-Alpes University Hospital, Boulevard de la Chantourne, Grenoble, 38000, France, Tel +33 669048426, Email Purpose: Percutaneous thermal ablation (PTA) is a cornerstone in the management of early-stage hepatocellular carcinoma (HCC). However, intrahepatic distant recurrence (IDR) occurs in the majority of patients after PTA. The aim of this study was to evaluate the immune signature associated with very early IDR. Patients and Methods: Thirty-one patients (26 men, 5 women; mean age:72.4 ± 8.6; age range:57– 86 years) who underwent PTA for HCC were included in this study. After PTA for HCC, patients were followed and later divided into two groups: a "very early recurrence" group in case of IDR within 12 months after PTA, and a "prolonged recurrence-free" group in case of no recurrence before 12 months of follow-up. Freshly harvested intratumoral and nontumoral liver tissues and peripheral blood were obtained before PTA and explored by multiparametric flow cytometry. Results: The frequency of PD1 + CD4 + T cells was higher in the early recurrence group than in the prolonged recurrence-free group in the peripheral blood (24.3%, IQR: 22.3– 36.5 vs 14.0%, IQR: 11.5– 16.4, p< 0.0001), in the nontumoral liver (37.9%, IQR: 36.0– 50.0 vs 22.5%, IQR: 18.0– 29.9, p=0.0004), and in the tumor (37.6%, IQR: 32.3– 39.3 vs 24.0%, IQR: 20.0– 30.3, p=0.0137). Similarly, the frequency of TIM + CD8 + T cells was higher in the very early recurrence group in the peripheral blood (p=0.0021), non-tumoral liver (p=0.0012), and tumor (p=0.0239). Conclusion: The expression of immune checkpoint molecules, such as PD1 and TIM3 on T cells identified HCC patients at risk of very early IDR after PTA who would likely benefit from adjuvant immunotherapy. Thus, our study contributes to a better understanding of the potential association of PTA with adjuvant immunotherapies. Keywords: immune checkpoint molecules, predictive factors, hepatocellular carcinoma, percutaneous thermal ablation, intrahepatic distant recurrence Percutaneous thermal ablation (PTA), including radiofrequency ablation (RFA) 1 and microwave ablation (MWA), 2 is a cornerstone of the management of early-stage hepatocellular carcinoma (HCC), together with surgical resection and liver transplantation. 3–5 PTA offers several advantages over surgery, such as a lower risk of complications, better tissue preservation, a lower cost, and a shorter hospital stay. 1 Despite the benefits, the rate of tumor recurrence after PTA therapy is still high. Intrahepatic distant recurrence (IDR) occurs in 60 to 80% of patients at 5 years after PTA, 1,5–7 similar to HCC surgical resection. 4,8 A cohort of 412 patients with small HCC who underwent PTA recently showed that IDR occurred in 47.1% of patients, and after a median time of only 8.4 months. 9 Alpha-fetoprotein (AFP) >100 ng/mL and tumor size were found to be predictive factors for IDR, 9 as well as multifocal lesions. 10 During the last decade, immunotherapies, mainly immune checkpoint inhibitors (ICIs), have emerged as promising cancer therapies. 11 While targeting the programmed cell death 1 (PD1) pathway in monotherapy failed to achieve statistically significant improvement in HCC patients, 12 the combination of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEG -Abstract Truncated-

Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience

Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis

Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials

Combinatorial Checkpoint Blockade and Laser Interstitial Thermal Therapy: A Single Center Study

Combination of Thermal Ablation and Activated Functional Killer Cells Immunotherapy for Cancer: A Retrospective Study.

In situ thermal ablation of tumors in combination with nano-adjuvant and immune checkpoint blockade to inhibit cancer metastasis and recurrence.

[Current Status and Progress of Thermal Ablation Combined with Immunotherapy for Lung Tumors]

143P Ablation Combined with Tislelizumab in Treating Hepatocellular Carcinoma: A Phase II Trial

Abstract 2468: Phase II study of cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma

Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients

Efficacy and Safety of Thermal Ablation for Solitary T1bN0M0 Papillary Thyroid Carcinoma: A Multicenter Study

Interventional oncological treatment of breast cancer liver metastasis (BCLM): single center long-term evaluation over 26 years using thermoablation techniques like LITT, MWA and TACE in a multimodal application

Efficacy and Safety of Thermal Ablation for Treatment of Solitary T1N0M0 Papillary Thyroid Carcinoma: A Multicenter Retrospective Study

Efficacy And Safety Of Thermal Ablation For Treatment Of Solitary T1n0m0 Papillary Thyroid Carcinoma: Multicenter Retrospective Study

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

Unexpected Anti-tumor Effect of Selective Internal Radiation Therapy and Radiofrequency Ablation Followed by Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Pulsed Electric Field Ablation versus Radiofrequency Thermal Ablation in Murine Breast Cancer Models: Anticancer Immune Stimulation, Tumor Response, and Abscopal Effects

PD1 and TIM3 Expression is Associated with Very Early Hepatocellular Carcinoma Recurrence After Percutaneous Thermal Ablation

Abscopal Effect of Stereotactic Radiotherapy Combined with Anti‐pd‐1/pd‐l1 Immunotherapy: Mechanisms, Clinical Efficacy, and Issues

Thermal Ablation for Papillary Thyroid Carcinoma

Abstract B014: Immuno-modulation of the tumor microenvironment of pancreatic adenocarcinoma following isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT)